Quick Answer
RHYTHM PHARMACEUTICALS, INC. reported Cash and Equivalents of $54.30 million for fiscal year 2025.
RHYTHM PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $54.30M | -39.1% |
| 2024 | $89.14M | +48.4% |
| 2023 | $60.08M | -52.9% |
| 2022 | $127.68M | +115.5% |
| 2021 | $59.25M | -41.3% |
| 2020 | $100.85M | +61.9% |
| 2019 | $62.29M | +25.7% |
| 2018 | $49.54M | +44.7% |
| 2017 | $34.24M | +423.5% |
| 2016 | $6.54M | -81.2% |
| 2015 | $34.87M | +22840.1% |
| 2014 | $152.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $52.08M | +9.6% | -61.6% |
| June 30, 2025 | $135.59M | -16.1% | +27.8% |
| March 31, 2025 | $106.09M | +98.6% | +19.0% |
| December 31, 2024 | $89.14M | +48.4% | +87.6% |
| September 30, 2024 | $47.52M | -26.4% | -70.6% |
| June 30, 2024 | $161.67M | +39.8% | +202.6% |
| March 31, 2024 | $53.43M | -51.3% | -11.1% |
| December 31, 2023 | $60.08M | -52.9% | -7.0% |
- RHYTHM PHARMACEUTICALS, INC. showed a decrease of -39.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2025 period, RHYTHM PHARMACEUTICALS, INC.’s cash and equivalents has grown by 35624.3% (from $152.0 thousand to $54.30 million).
- The most recent figure is from RHYTHM PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: